Responses
Late-Breaking Abstracts
Clinical Trial in Progress
1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
